South Korea
· Delayed Price · Currency is KRW Curiox Biosystems Statistics
Total Valuation
Curiox Biosystems has a market cap or net worth of KRW 312.60 billion. The enterprise value is 300.35 billion.
| Market Cap | 312.60B |
| Enterprise Value | 300.35B |
Important Dates
The last earnings date was Thursday, November 14, 2024.
| Earnings Date | Nov 14, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Curiox Biosystems has 16.10 million shares outstanding. The number of shares has increased by 80.11% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 16.10M |
| Shares Change (YoY) | +80.11% |
| Shares Change (QoQ) | +0.04% |
| Owned by Insiders (%) | 17.75% |
| Owned by Institutions (%) | 14.02% |
| Float | 11.28M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 53.69 |
| PB Ratio | 6.39 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -27.54 |
| EV / Sales | 52.72 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -31.66 |
Financial Position
The company has a current ratio of 7.67, with a Debt / Equity ratio of 0.02.
| Current Ratio | 7.67 |
| Quick Ratio | 6.69 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.09 |
| Interest Coverage | -379.55 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Capital (ROIC) | n/a |
| Revenue Per Employee | 237.37M |
| Profits Per Employee | -454.33M |
| Employee Count | 24 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +58.72% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +58.72% |
| 50-Day Moving Average | 21,480.80 |
| 200-Day Moving Average | 22,156.33 |
| Relative Strength Index (RSI) | 34.36 |
| Average Volume (20 Days) | 268,175 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Curiox Biosystems had revenue of KRW 5.70 billion and -10.90 billion in losses. Loss per share was -692.37.
| Revenue | 5.70B |
| Gross Profit | 2.91B |
| Operating Income | -12.05B |
| Pretax Income | -11.15B |
| Net Income | -10.90B |
| EBITDA | -9.95B |
| EBIT | -12.05B |
| Loss Per Share | -692.37 |
Balance Sheet
The company has 13.08 billion in cash and 829.66 million in debt, giving a net cash position of 12.25 billion or 761.23 per share.
| Cash & Cash Equivalents | 13.08B |
| Total Debt | 829.66M |
| Net Cash | 12.25B |
| Net Cash Per Share | 761.23 |
| Equity (Book Value) | 48.82B |
| Book Value Per Share | 3,038.24 |
| Working Capital | 13.92B |
Cash Flow
In the last 12 months, operating cash flow was -9.47 billion and capital expenditures -14.36 million, giving a free cash flow of -9.49 billion.
| Operating Cash Flow | -9.47B |
| Capital Expenditures | -14.36M |
| Free Cash Flow | -9.49B |
| FCF Per Share | -589.37 |
Margins
Gross margin is 51.01%, with operating and profit margins of -211.53% and -191.41%.
| Gross Margin | 51.01% |
| Operating Margin | -211.53% |
| Pretax Margin | -195.71% |
| Profit Margin | -191.41% |
| EBITDA Margin | -174.68% |
| EBIT Margin | -211.53% |
| FCF Margin | -166.53% |
Dividends & Yields
Curiox Biosystems does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -80.11% |
| Shareholder Yield | -80.11% |
| Earnings Yield | -3.57% |
| FCF Yield | -3.03% |
Stock Splits
The last stock split was on August 6, 2024. It was a forward split with a ratio of 2.
| Last Split Date | Aug 6, 2024 |
| Split Type | Forward |
| Split Ratio | 2 |
Scores
Curiox Biosystems has an Altman Z-Score of 47.24.
| Altman Z-Score | 47.24 |
| Piotroski F-Score | n/a |